Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation

Journal of the American College of Cardiology

Volumn 36, Issue 3, 2000, Pages 685-692

  Hasdai, David ^a   Harrington, Robert A ^b   Hochman, Judith S ^c   Califf, Robert M ^b   Battler, Alexander ^a   Box, James W ^b   Simoons, Maarten L ^d   Deckers, Jaap ^d   Topol, Eric J ^e   Holmes Jr , David R ^f  

^a RABIN MEDICAL CENTER   (Israel)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d CARDIALYSIS   (Netherlands)

^e LERNER RESEARCH INSTITUTE   (United States)

^f MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPTIFIBATIDE; FIBRINOGEN RECEPTOR; PLACEBO;

ARTICLE; CARDIOGENIC SHOCK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; ST SEGMENT ELEVATION; SURVIVAL TIME; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

AGED; BLOOD PLATELETS; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HEART-ASSIST DEVICES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; SHOCK; SYNDROME; TIME FACTORS;

EID: 0033851373     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)00814-7     Document Type: Article

References (22)

1. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
2. Cardiogenic shock complicating myocardial infarction
3. An international, randomized, controlled trial of lamifiban, a platelet glycoprotein IIb/IIIa inhibitor, heparin or both in unstable angina
4. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
5. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
6. Inhibition of the platelet glycoprotein IIb/IIIa with tirofiban in unstable angina and non-Q-wave myocardial infarction
7. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes without persistent ST-segment elevation: A randomized, placebo-controlled, clinical trial
8. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
9. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
10. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary interventions. IMPACT-II
11. Use of c7E3 Fab in conjunction with primary coronary stenting for acute myocardial infarction complicated by cardiogenic shock
12. Adjunctive use of abciximab improves clinical outcomes in acute myocardial infarction patients presenting with cardiogenic shock
13. The meaning and use of the area under a receiver operating characteristics (ROC) curve
14. Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction
15. Cardiogenic shock complicating acute myocardial infarction: Predictors of mortality
16. Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation
17. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta-3 blockade with percutaneous coronary interventions. EPIC Investigator Group
18. Pacifying the infarct vessel
19. Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation
20. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. C7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators
21. Temporal trends in cardiogenic shock complicating acute myocardial infarction